Neuropathic Pain Project Licensed by Signal Pharma
Signal Pharma has licensed a joint University of Aberdeen / University of Toronto programme for the treatment of neuropathic and inflammatory pain
A second project from the Kosterlitz Centre for Therapeutics has been licensed by Signal Pharma: cannabinoid receptor type 1 (CB1) allosteric enhancers for the treatment of different types of pain, for which existing treatments (opiates and NSAIDs) are generally ineffective. Signal has licensed a patent from the Universities of Toronto and Aberdeen featuring new compounds (CB1 PAMs) which have shown impressive potential in pre-clinical studies. Signal has provided the matched funding for a successful Canadian Institutes of Health Proof of Principle Phase II application.